NCT03360162

Brief Summary

The use of ultrasonography in detecting giant cell arteritis ( GCA) is emerging. Currently, temporal biopsy is the gold standard to diagnose GCA but studies have shown the interest to use B mode ultrasonography. However, until now, the study of velocities in GCA have not been yet performed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 2, 2017

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

November 28, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 4, 2017

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2017

Completed
Last Updated

April 21, 2020

Status Verified

April 1, 2020

Enrollment Period

1 month

First QC Date

November 28, 2017

Last Update Submit

April 20, 2020

Conditions

Horton Disease

Outcome Measures

Primary Outcomes (1)

  • Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler

    velocimetric temporal arterial study in giant arteritis

    2 months

Secondary Outcomes (1)

  • evaluation of the halo sign in giant arteritis using B mode ultrasonography

    2 months

Eligibility Criteria

Age55 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

all patients aged more than 55 years old who are suspected of giant arteritis

You may qualify if:

  • patients with suspicious giant arteritis

You may not qualify if:

  • patients who have already been treated or diagnosed for giant arteritis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHRU de Brest

Brest, 29609, France

Location

MeSH Terms

Conditions

Giant Cell Arteritis

Condition Hierarchy (Ancestors)

Vasculitis, Central Nervous SystemAutoimmune Diseases of the Nervous SystemNervous System DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular DiseasesArteritisVasculitisSkin Diseases, VascularSkin DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 28, 2017

First Posted

December 4, 2017

Study Start

November 2, 2017

Primary Completion

December 10, 2017

Study Completion

December 10, 2017

Last Updated

April 21, 2020

Record last verified: 2020-04

Locations

FR(1)